A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Inclusion Criteria:

• Histopathological diagnosis of amyloidosis based on detection byimmunohistochemistry and polarizing light microscopy of green bi-refringent materialin congo red stained tissue specimens (in an organ other than bone marrow) orcharacteristic electron microscopy appearance

• Measurable disease of amyloid light-chain (AL) amyloidosis as defined by at leastone of the following:

1. serum monoclonal (M)-protein greater than or equal (>=) 0.5 grams/deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis andimmunofixation [IFE] performed at a central laboratory)

2. serum free light chain greater than or equal to (>=) 50 milligram/Liter (mg/L)with an abnormal kappa:lambda ratio or the difference between involved anduninvolved free light chains (dFLC) >= 50 mg/L

• One or more organs impacted by AL amyloidosis according to consensus guidelines

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2

Exclusion Criteria:

• Prior therapy for AL amyloidosis or multiple myeloma including medications thattarget CD38, with the exception of 160 mg dexamethasone (or equivalentcorticosteroid) maximum exposure prior to randomization

• Previous or current diagnosis of symptomatic multiple myeloma, including thepresence of lytic bone disease, plasmacytomas, >= 60 percent (%) plasma cells in thebone marrow, or hypercalcemia

• Evidence of significant cardiovascular conditions as specified below:

1. NT-ProBNP > 8500 nanogram per liter (ng/L)

2. New York Heart Association (NYHA) classification IIIB or IV heart failure

3. Heart failure that in the opinion of the investigator is on the basis ofischemic heart disease (eg, prior myocardial infarction with documented historyof cardiac enzyme elevation and electrocardiogram [ECG] changes) or uncorrectedvalvular disease and not primarily due to AL amyloid cardiomyopathy

4. Inpatient admission to a hospital for unstable angina or myocardial infarctionwithin the last 6 months prior to first dose or percutaneous cardiacintervention with recent stent within 6 months or coronary artery bypassgrafting within 6 months

5. For participants with congestive heart failure, cardiovascular-relatedhospitalizations within 4 weeks prior to randomization

6. Participants with a history of sustained ventricular tachycardia or abortedventricular fibrillation or with a history of atrioventricular (AV) nodal orsinoatrial (SA) nodal dysfunction for which a pacemaker/implantablecardioverter-defibrillators [ICD] is indicated but not placed (participants whodo have a pacemaker/ICD are allowed on study)

7. Screening 12-lead ECG showing a baseline QT interval as corrected byFridericia's formula (QTcF) > 500 milliseconds (msec). Participants who have apacemaker may be included regardless of calculated QTc interval

8. Supine systolic blood pressure < 90 millimeter of mercury (mmHg), orsymptomatic orthostatic hypotension, defined as a decrease in systolic bloodpressure upon standing of > 20 mmHg despite medical management (eg, midodrine,fludrocortisones) in the absence of volume depletion

• Planned stem cell transplant during the first 6 cycles of protocol therapy areexcluded. Stem cell collection during the first 6 cycles of protocol therapy ispermitted

• Known to be seropositive for human immunodeficiency virus (HIV)

• Any one of the following:

1. Seropositive for hepatitis B (defined by a positive test for hepatitis Bsurface antigen [HBsAg]). Participants with resolved infection (ie,participants who are HBsAg negative but positive for antibodies to hepatitis Bcore antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR)measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels.Those who are PCR positive will be excluded

2. Known to be seropositive for hepatitis C (except in the setting of a sustainedvirologic response [SVR], defined as aviremia at least 12 weeks aftercompletion of antiviral therapy)

• Grade 2 sensory or Grade 1 painful peripheral neuropathy